ITGAX and cancer: The identification of a specific sub-set of DCs with the highest adjuvanticity as well as a better understanding of the mechanisms of their adjuvanticity lays a foundation for further investigations and comparison of CD11c+ MCHIIlo cell sub-population to a possible human DC counterpart in order to use DCs as highly effective adjuvants in neoepitope-based cancer vaccines.